Chemotherapy and Standard Treatment Options

  • Mary HesdorfferEmail author
  • Gleneara E. Bates-PappasEmail author


In a rare aggressive malignancy, any positive movement, no matter how small, is reported upon in “glowing terms.” In other malignancies, this chapter could stretch to the size of an entire book, but unfortunately, in malignant mesothelioma, to date, there is only one FDA-approved treatment and no approved second-line treatment. Providing a weighty chapter is impossible in a disease, which historically has had little in the way of developments since the approval of pemetrexed and cisplatin.

During my time as an oncology nurse and executive director of the Mesothelioma Applied Research Foundation, I have been a part of and offered my clinical expertise on more two dozen clinical trials using various chemotherapeutic combinations. This chapter will draw from my expertise as a nurse and while providing a historical context and practical tools for caring for mesothelioma patients during chemotherapy.


  1. Bearz A, Talamini R, Rossoni G, et al. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes. 2012;5:482.CrossRefGoogle Scholar
  2. Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(Suppl 2):S304–10. Review. PubMed PMID: 29507800; PubMed Central PMCID: PMC5830568.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Goudar RK. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma. Ther Clin Risk Manag. 2008;4(1):205–11.CrossRefGoogle Scholar
  4. Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer. 2003;88(2):167–74. CrossRefGoogle Scholar
  5. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. A to Z list of cancer drug National Cancer Institute. 2018. Retrieved August 16, 2018, from
  6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.CrossRefGoogle Scholar
  7. Zauderer MG, Kass SL, Woo K, et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014;84:271–4.CrossRefGoogle Scholar
  8. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–14.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Mesothelioma Applied Research FoundationAlexandriaUSA
  2. 2.City University of New YorkGraduate CenterNew YorkUSA

Personalised recommendations